Presilium Private Wealth LLC Takes $703,000 Position in Novartis AG $NVS

Presilium Private Wealth LLC acquired a new position in Novartis AG (NYSE:NVS) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 4,605 shares of the company’s stock, valued at approximately $703,000.

Other institutional investors have also recently made changes to their positions in the company. Fisher Asset Management LLC increased its holdings in Novartis by 1.7% in the 3rd quarter. Fisher Asset Management LLC now owns 7,239,366 shares of the company’s stock valued at $928,376,000 after acquiring an additional 117,952 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Novartis by 18.1% during the third quarter. JPMorgan Chase & Co. now owns 537,543 shares of the company’s stock valued at $68,935,000 after buying an additional 82,226 shares during the last quarter. BXM Wealth LLC grew its holdings in Novartis by 726.9% during the 4th quarter. BXM Wealth LLC now owns 42,817 shares of the company’s stock valued at $5,903,000 after buying an additional 37,639 shares in the last quarter. Spire Wealth Management grew its holdings in Novartis by 2,561.0% during the 4th quarter. Spire Wealth Management now owns 38,983 shares of the company’s stock valued at $5,375,000 after buying an additional 37,518 shares in the last quarter. Finally, AlphaCore Capital LLC boosted its position in shares of Novartis by 197.1% during the 3rd quarter. AlphaCore Capital LLC now owns 22,964 shares of the company’s stock valued at $2,945,000 after acquiring an additional 15,235 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Trading Up 3.0%

Shares of NVS opened at $153.42 on Wednesday. The company’s fifty day simple moving average is $148.97 and its 200-day simple moving average is $149.16. The company has a market cap of $292.75 billion, a P/E ratio of 21.98, a P/E/G ratio of 2.62 and a beta of 0.46. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. Novartis AG has a twelve month low of $112.34 and a twelve month high of $170.46.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing the consensus estimate of $2.11 by ($0.12). The firm had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The business’s revenue for the quarter was down .9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.28 earnings per share. As a group, analysts expect that Novartis AG will post 8.82 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NVS. Weiss Ratings cut shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Argus upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Wednesday, March 11th. Morgan Stanley upped their target price on shares of Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research report on Thursday, March 26th. Finally, Sanford C. Bernstein upgraded Novartis to a “hold” rating in a research report on Thursday, March 19th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Novartis presently has a consensus rating of “Hold” and an average target price of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.